<section class="hero">
  <div class="container">
    <div class="category">The Regulatory Series</div>
    <h1>The Day the Peptide<br>Rules <em>Changed</em></h1>
    <p class="dek">On February 27, 2026, the FDA quietly began undoing two years of peptide restrictions. The Federal Register confirmed it on April 15. Here are the fourteen peptides expected to return, and the five likely to remain restricted.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">On February 27, 2026, on a recording of <em>The Joe Rogan Experience</em>, United States Department of Health and Human Services Secretary Robert F. Kennedy Jr. said that within a couple of weeks the FDA would begin reversing two years of compounding restrictions on a class of widely used peptides. The promise landed in the Federal Register on April 15, 2026, and took effect a week later, on April 22.</p>

    <p>The next major milestone is a Pharmacy Compounding Advisory Committee meeting on July 23, 2026, with a second session on July 24 and a follow-up scheduled before the end of February 2027.</p>

    <p>This is the most consequential regulatory shift in peptide medicine in a decade. Here is what the original 2023 restrictions did, what the April 15 action formalized, which fourteen peptides are expected to return to legal compounding, and which five are not.</p>

    <h2>What the 2023 restrictions actually did</h2>

    <p>In late 2023, the FDA placed nineteen peptides on what is informally known as the Category 2 list. The category designates substances that the agency has flagged as presenting safety concerns for compounding under section 503A. In practice, being placed on Category 2 means a 503A pharmacy cannot legally compound the peptide for an individual patient, even with a prescription, until the FDA completes its review.</p>

    <p>The list included peptides that had become widely used in clinical practice for tissue repair, growth hormone signaling, immune modulation, and cellular longevity research. BPC-157, TB-500, Selank, Semax, MOTS-c, Epitalon, GHK-Cu in injectable form, and a number of others were among them. For two years, the only legal way to access most of these molecules was through clinical trials or through international gray-market sources, with all the safety questions those routes raise.</p>

    <h2>What February 27 actually said</h2>

    <p>Kennedy's announcement on the Rogan podcast was a policy signal, not a legal action. It directed the FDA to begin moving the majority of the Category 2 peptides off the restricted list. The mechanical work of doing so happened through a different procedural route: the original entities that had nominated each peptide for Category 2 designation voluntarily withdrew those nominations.</p>

    <p>That withdrawal sequence resolved on April 15, 2026, when the FDA published the formal removal in the Federal Register. The removal of twelve peptides from Category 2 took effect seven days later, on April 22, 2026. Combined with five peptides whose nominations had been withdrawn earlier, in September 2024, fourteen peptides have now exited Category 2 status. Five remain on the restricted list, primarily because of safety concerns, misuse potential, or proximity to existing FDA-approved drug categories.</p>

    
    <div class="timeline-wrap">
      <svg viewBox="0 0 680 220" xmlns="http://www.w3.org/2000/svg" aria-label="Regulatory timeline of the Category 2 peptide reversal">
        
        <line x1="60" y1="100" x2="620" y2="100" stroke="#730e07" stroke-width="1" opacity="0.5"></line>

        
        <g>
          <circle cx="60" cy="100" r="6" fill="#730e07"></circle>
          <text x="60" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="20" font-weight="500" fill="#1a1614">Late 2023</text>
          <text x="60" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">CATEGORY 2</text>
          <text x="60" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">19 peptides placed</text>
          <text x="60" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">under restriction</text>
        </g>

        
        <g>
          <circle cx="246" cy="100" r="6" fill="#730e07"></circle>
          <text x="246" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="20" font-weight="500" fill="#1a1614">Feb 27, 2026</text>
          <text x="246" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">RFK ON ROGAN</text>
          <text x="246" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">FDA action signaled</text>
          <text x="246" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">"within weeks"</text>
        </g>

        
        <g>
          <circle cx="434" cy="100" r="6" fill="#730e07"></circle>
          <text x="434" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="20" font-weight="500" fill="#1a1614">Apr 15, 2026</text>
          <text x="434" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">FEDERAL REGISTER</text>
          <text x="434" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">12 peptides removed</text>
          <text x="434" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">effective Apr 22</text>
        </g>

        
        <g>
          <circle cx="620" cy="100" r="8" fill="#730e07" stroke="#faf6f0" stroke-width="2"></circle>
          <circle cx="620" cy="100" r="14" fill="none" stroke="#730e07" stroke-width="1" opacity="0.4"></circle>
          <text x="620" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="20" font-weight="600" fill="#730e07">Jul 23, 2026</text>
          <text x="620" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">PCAC REVIEW</text>
          <text x="620" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">First evaluation</text>
          <text x="620" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">meeting</text>
        </g>
      </svg>
      <div class="timeline-caption">Two years of restriction, two months of unwinding</div>
    </div>

    <h2>Removal is not approval, yet</h2>

    <p>Removal from Category 2 is not the same as Category 1 status. It means the FDA is no longer flagging the substance as a safety concern, but each peptide still requires individual evaluation by the Pharmacy Compounding Advisory Committee, the standing FDA body that determines what substances may be added to the 503A bulks list. PCAC review is the technical foundation on which compounding eligibility decisions rest.</p>

    <p>The first review meeting is scheduled for July 23 and 24, 2026. A second is expected before the end of February 2027. Together, those two sessions will determine the order and timeline for each peptide's return to active 503A compounding.</p>

    <h2>The fourteen peptides expected to return</h2>

    <p>Across the September 2024 withdrawals and the April 15, 2026 removal, fourteen peptides are expected to clear PCAC review and ultimately reach Category 1 status. They span seven therapeutic areas.</p>

    
    <div class="peptides-section">

      
      <div class="peptide-block returning">
        <div class="peptide-block-header">14 Peptides Returning to Category 1</div>
        <div class="peptide-block-subhead">Expected to clear PCAC review</div>
        <div class="peptide-grid-14">

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Healing</div>
            <div class="peptide-chip-name">BPC-157</div>
            <div class="peptide-chip-use">Tissue repair, gut healing, inflammation.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Healing</div>
            <div class="peptide-chip-name">TB-500</div>
            <div class="peptide-chip-use">Wound healing, muscle recovery.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Immune</div>
            <div class="peptide-chip-name">Thymosin Alpha-1</div>
            <div class="peptide-chip-use">Immune modulation. Approved in over 35 countries.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Metabolic</div>
            <div class="peptide-chip-name">AOD-9604</div>
            <div class="peptide-chip-use">Fat metabolism. Formerly TGA-approved in Australia.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Growth Hormone</div>
            <div class="peptide-chip-name">Ipamorelin</div>
            <div class="peptide-chip-use">GH secretion, body composition, sleep.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Growth Hormone</div>
            <div class="peptide-chip-name">CJC-1295</div>
            <div class="peptide-chip-use">GH release, often paired with Ipamorelin.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Cognitive</div>
            <div class="peptide-chip-name">Selank</div>
            <div class="peptide-chip-use">Anxiety, cognitive function. Approved in Russia.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Cognitive</div>
            <div class="peptide-chip-name">Semax</div>
            <div class="peptide-chip-use">Neuroprotection. Approved in Russia and Ukraine.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Skin / Healing</div>
            <div class="peptide-chip-name">GHK-Cu</div>
            <div class="peptide-chip-use">Collagen synthesis, wound healing, hair growth.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Immune</div>
            <div class="peptide-chip-name">KPV</div>
            <div class="peptide-chip-use">Anti-inflammatory, gut inflammation.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Longevity</div>
            <div class="peptide-chip-name">MOTS-c</div>
            <div class="peptide-chip-use">Mitochondrial function, insulin sensitivity.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Longevity</div>
            <div class="peptide-chip-name">Epitalon</div>
            <div class="peptide-chip-use">Telomerase activation, pineal regulation.</div>
          </div>

          <div class="peptide-chip">
            <div class="peptide-chip-tag">Hormonal</div>
            <div class="peptide-chip-name">Kisspeptin-10</div>
            <div class="peptide-chip-use">Reproductive hormone regulation.</div>
          </div>
          <div class="peptide-chip">
            <div class="peptide-chip-tag">Sleep</div>
            <div class="peptide-chip-name">DSIP</div>
            <div class="peptide-chip-use">Sleep architecture, stress response.</div>
          </div>

        </div>
      </div>

      
      <div class="peptide-block restricted">
        <div class="peptide-block-header">5 Likely Remaining Restricted</div>
        <div class="peptide-block-subhead">Safety concerns, limited evidence, or misuse potential</div>
        <div class="peptide-grid-5">

          <div class="peptide-restricted">
            <div class="peptide-restricted-name">Melanotan II</div>
            <div class="peptide-restricted-concern">CV &amp; melanoma risk</div>
            <div class="peptide-restricted-detail">Linked to nausea, blood-pressure changes, and melanocyte-stimulation concerns.</div>
          </div>

          <div class="peptide-restricted">
            <div class="peptide-restricted-name">GHRP-2</div>
            <div class="peptide-restricted-concern">Off-target hormones</div>
            <div class="peptide-restricted-detail">Elevates cortisol and prolactin. Not selective for GH like Ipamorelin.</div>
          </div>

          <div class="peptide-restricted">
            <div class="peptide-restricted-name">GHRP-6</div>
            <div class="peptide-restricted-concern">Off-target + appetite</div>
            <div class="peptide-restricted-detail">Same cortisol and prolactin issues as GHRP-2, plus pronounced appetite stimulation.</div>
          </div>

          <div class="peptide-restricted">
            <div class="peptide-restricted-name">LL-37</div>
            <div class="peptide-restricted-concern">Limited safety data</div>
            <div class="peptide-restricted-detail">Antimicrobial peptide with very limited human safety data for systemic compounding.</div>
          </div>

          <div class="peptide-restricted">
            <div class="peptide-restricted-name">PEG-MGF</div>
            <div class="peptide-restricted-concern">Sparse clinical data</div>
            <div class="peptide-restricted-detail">PEGylated growth factor with minimal published human evidence.</div>
          </div>

        </div>
      </div>

    </div>

    
    <div class="pullquote">
      <p>For two years, the trajectory was tightening. As of April 22, it has <span class="mark">reversed</span>.</p>
    </div>

    <h2>What happens next</h2>

    <p>Removal from Category 2 is the first procedural step. The full path from restricted substance to a vial in your refrigerator runs through several more.</p>

    
    <div class="next-steps">
      <div class="next-steps-title">The path each peptide will follow</div>
      <ol>
        <li><strong>PCAC review.</strong> The Pharmacy Compounding Advisory Committee evaluates each peptide on its merits. First meeting is July 23 and 24, 2026; the second is scheduled before the end of February 2027.</li>
        <li><strong>FDA proposed rule.</strong> The agency publishes a Federal Register notice with its proposed inclusion or exclusion for each substance.</li>
        <li><strong>Public comment period.</strong> A defined window for clinicians, patients, pharmacies, and other stakeholders to submit comments.</li>
        <li><strong>FDA final ruling.</strong> The agency issues a final rule that incorporates the PCAC recommendation and the public comments.</li>
        <li><strong>Addition to the 503A bulks list.</strong> Compounding pharmacies are then authorized to fill prescriptions for the peptide.</li>
      </ol>
    </div>

    <p>For most of the fourteen peptides, the most likely timeline for the first additions to begin reaching pharmacies is the second half of 2026 and through 2027. The exact order will be set by the PCAC sessions.</p>

    <h2>What this means for patients</h2>

    <p>For patients waiting on these peptides, the practical effect right now is patience. Nothing has yet returned to a pharmacy near you. The legal path back is now defined and active. The first prescriptions of formerly restricted peptides will be filled when each peptide completes its formal reclassification, likely beginning in the second half of 2026.</p>

    <p>For the broader peptide market, the February announcement and the April 15 Federal Register notice together mark the end of the post-2023 restriction era. The next chapter is one in which more peptides are legally available, prescribed by physicians, compounded by licensed pharmacies, and accompanied by the documentation patients should expect from prescription medicine.</p>

    <h2>Where pru sits in this</h2>

    <p>At <span class="brand-mark">pru</span>, our protocols for the peptides expected to return have been built and ready for thirty days post-Federal Register notice. As each peptide completes its reclassification, it will be added to the <span class="brand-mark">pru</span> formulary on the same terms as every other therapy: prescribed by a licensed clinician, compounded at a state-licensed 503A pharmacy, and accompanied by a Certificate of Analysis on every batch. The science and the regulatory framework are converging. The transparency we have built around peptide therapy will scale with them.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>U.S. Food and Drug Administration. <em>Federal Register Notice: Removal of Bulk Drug Substances from Category 2 of the Interim 503A Bulks List,</em> April 15, 2026 (effective April 22, 2026).</li>
      <li>U.S. Food and Drug Administration. <em>Pharmacy Compounding Advisory Committee Meeting Notice: July 23 and 24, 2026 sessions on 503A bulks list peptide candidates.</em> fda.gov/advisory-committees.</li>
      <li>U.S. Food and Drug Administration. <em>Compounding and the FDA: 503A Bulks List Categorization.</em> fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act.</li>
      <li>Hyman, Phelps &amp; McNamara, P.C. <em>"FDA's Pep(tide) Rally! What Compounders and Industry Need to Know."</em> FDA Law Blog, April 2026.</li>
      <li>Orrick, Herrington &amp; Sutcliffe LLP. <em>"FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings."</em> Insights, April 2026.</li>
      <li>BioPharma Dive. <em>"FDA moves toward easing restrictions on certain peptides,"</em> April 16, 2026.</li>
      <li>STAT News. <em>"RFK Jr.'s peptide push could unleash risky drugs,"</em> First Opinion, April 29, 2026.</li>
      <li>Drug Quality and Security Act of 2013. <em>Public Law 113-54.</em> Codified at 21 U.S.C. §§ 353a (Section 503A) and 353b (Section 503B).</li>
      <li><em>The Joe Rogan Experience.</em> Episode featuring HHS Secretary Robert F. Kennedy Jr., February 27, 2026. (Public statement of forthcoming FDA action.)</li>
    </ol>
  </div>
</section>

On February 27, 2026, RFK Jr. announced on the Joe Rogan Experience that the FDA would begin reversing two years of peptide restrictions. The Federal Register confirmed it on April 15. Here are the 14 peptides expected to return, and the 5 likely to remain restricted.

On February 27, 2026, the FDA quietly began undoing two years of peptide restrictions. The Federal Register confirmed it on April 15. Here are the fourteen peptides expected to return, and the five likely to remain restricted.

The Day the Peptide Rules Changed

<section class="hero">
  <div class="container">
    <div class="category">The Culture Series</div>
    <h1>Hollywood's<br><em>Worst-Kept Secret</em></h1>
    <p class="dek">The Ozempic body headlines barely scratch the surface. Glutathione, NAD+, and sermorelin are quietly rewriting Hollywood's relationship with aging, recovery, and red-carpet prep.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">The "Ozempic body" headlines started in late 2022 and have not stopped. Variety, the New York Times, and the Hollywood Reporter have all covered the same story from slightly different angles: a class of injectable peptide medications has changed how the entertainment industry thinks about weight, recovery, and red-carpet preparation. The headlines focus on weight loss because weight loss is photographable. The actual story is broader.</p>

    <p>Behind the scenes of that story is a quieter set of peptides that Hollywood has been using for years and that the public press is only starting to catch up to. Glutathione. NAD+. Sermorelin. Each one does something different. None of them are visible at the box office. All of them are showing up in clinic intake forms and drip-bar menus in Beverly Hills, Tribeca, and SoHo.</p>

    <h2>The Ozempic era, briefly</h2>

    <p>Semaglutide and tirzepatide, sold under the brand names Ozempic, Wegovy, Mounjaro, and Zepbound, moved from diabetes management to mainstream weight management to celebrity discussion in roughly three years. Oprah Winfrey publicly disclosed her use of a GLP-1 weight-loss medication in late 2023. Elon Musk attributed his weight loss to Wegovy in a 2022 social-media post. Sharon Osbourne, Tracy Morgan, Whoopi Goldberg, and Chelsea Handler have each discussed their own experiences with GLP-1 medications in interviews and on their respective shows.</p>

    <p>This is the part of the story that the public talks about. The trade press, including Variety, the Hollywood Reporter, and the New York Times Style section, has reported widespread use of GLP-1s ahead of awards seasons, film premieres, and major press tours. Producers and publicists have described a tightening calendar of pre-event preparation that increasingly includes a peptide program.</p>

    <h2>The iceberg below the headlines</h2>

    <p>Ozempic is the visible tip. Below the surface, three other peptides are reshaping the work that goes into looking the way actors look, and recovering from the work that goes into the work.</p>

    
    <div class="peptide-comp">
      <div class="peptide-comp-header">Three peptides below the headlines</div>
      <div class="peptide-grid">
        <div class="pept-card">
          <div class="pept-eyebrow">Below The Headline I</div>
          <div class="pept-name">Glutathione</div>
          <div class="pept-row">
            <div class="pept-label">What it is</div>
            <div class="pept-text">A tripeptide your liver makes from cysteine, glycine, and glutamate. The body's master antioxidant.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Neutralizes free radicals, protects mitochondria, and supports the liver's detoxification pathways.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Why Hollywood</div>
            <div class="pept-text">The flagship of celebrity drip culture. Skin brightening before red-carpet events, recovery after.</div>
          </div>
        </div>

        <div class="pept-card">
          <div class="pept-eyebrow">Below The Headline II</div>
          <div class="pept-name">NAD+</div>
          <div class="pept-row">
            <div class="pept-label">What it is</div>
            <div class="pept-text">A coenzyme in every living cell that powers basic metabolism. Levels fall steeply with age.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Drives mitochondrial energy production, fuels sirtuin longevity proteins, and supports DNA repair.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Why Hollywood</div>
            <div class="pept-text">The longevity-clinic drip popularized by Bryan Johnson. A pre-event and recovery ritual.</div>
          </div>
        </div>

        <div class="pept-card">
          <div class="pept-eyebrow">Below The Headline III</div>
          <div class="pept-name">Sermorelin</div>
          <div class="pept-row">
            <div class="pept-label">What it is</div>
            <div class="pept-text">A synthetic copy of growth hormone-releasing hormone (GHRH), the signal your pituitary uses to make growth hormone.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Tells the pituitary to release more of your own growth hormone, in pulses that mimic younger biology.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Why Hollywood</div>
            <div class="pept-text">Faster recovery from training and filming. Better sleep. Slower muscle and skin aging.</div>
          </div>
        </div>
      </div>
    </div>

    <h2>Glutathione and the drip-bar economy</h2>

    <p>Glutathione is a small peptide your liver produces, made from three amino acids: cysteine, glycine, and glutamate. It is the body's master antioxidant. It binds and neutralizes oxidative byproducts of normal cellular metabolism, protects mitochondria, and supports the liver's detoxification pathways.</p>

    <p>Hollywood has used it for years, primarily in IV form, for what trade press describes as a brightening and recovery effect on skin. Drip lounges in Los Angeles, New York, and Miami have built much of their business model around glutathione protocols. Vogue, Allure, and Harper's Bazaar have profiled the trend across multiple cycles. The injectable version, prescribed and compounded for individual patients, is the at-home equivalent of the drip-lounge ritual, with the pharmacy chain of custody intact.</p>

    <h2>NAD+ and the longevity drip</h2>

    <p>NAD+ has moved from longevity-research circles into mainstream wellness in roughly five years, propelled by public figures like Bryan Johnson, whose daily protocol is documented across his media presence, and a wave of biohacker podcasters who have made the molecule a household word in the wellness audience. NAD+ levels in cells decline with age, which has driven a market for both intravenous and injectable replacement.</p>

    <p>In Hollywood, NAD+ drips have become routine pre-event and post-event therapy at high-end longevity clinics. The injectable version, available through 503A pharmacies, is a more efficient and lower-cost alternative for patients who want regular access without the clinic visit.</p>

    <h2>Sermorelin and the growth hormone revival</h2>

    <p>Sermorelin is a synthetic version of growth hormone-releasing hormone (GHRH), a peptide your body makes to tell your pituitary gland to release growth hormone. In your twenties, this signaling system runs strong. Growth hormone supports muscle quality, recovery, sleep architecture, and skin elasticity. By your forties, the signal is quieter. Sermorelin restores some of the volume of that signal.</p>

    <p>The Hollywood Reporter and Allure have profiled clinics and physicians who prescribe sermorelin to actors and athletes who want to recover from training and filming faster. The molecule does not deliver growth hormone directly. It asks the body to make more of its own.</p>

    <h2>Why Hollywood was first</h2>

    <p>The entertainment industry has always been a leading indicator for personal-care technology because the financial stakes of looking a particular way at a particular time are unusually high. Pre-shoot weight changes, post-injury recovery, anti-aging maintenance, and pre-event preparation have always existed. What is new is the precision of the tools available.</p>

    <p>Peptides do not replace the work. Actors and athletes still train, still diet, still sleep. The peptides change the recovery curve, the metabolic curve, and the cellular maintenance curve. The result is a smaller gap between what the body is biologically capable of and what the role demands.</p>

    
    <div class="pullquote">
      <p>Hollywood is not using a different product. It is using the same molecules, with <span class="mark">earlier access</span>.</p>
    </div>

    <h2>What it means for everyone else</h2>

    <p>The fact that Hollywood has been using these molecules longer than the public conversation has known about them does not make the molecules better or worse. It does mean the cultural moment is real. It also means the demand has moved into the general public, and the responsibility to deliver these therapies safely has expanded with it.</p>

    <p>At <span class="brand-mark">pru</span>, the same molecules that the entertainment industry has been using quietly for years are available to any patient with a valid prescription, prescribed by a licensed clinician, compounded at a 503A pharmacy, and accompanied by a Certificate of Analysis on every batch. The Hollywood version of these therapies and the responsible-clinic version are not different products. They are the same molecules, dispensed under the same standards. The difference is access.</p>

    <p>The mainstreaming of peptide medicine is not Hollywood reaching down. It is the rest of the country catching up.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>Wallace, A. (2023). Interview with Oprah Winfrey on weight-loss medication. <em>People Magazine</em>, December 2023. (Public disclosure of GLP-1 use.)</li>
      <li>Musk, E. (2022). Public statement attributing weight loss to fasting and Wegovy. Twitter (now X), October 2022.</li>
      <li>Trade press coverage of GLP-1 medications and pre-event preparation in entertainment: <em>Variety</em>, <em>The Hollywood Reporter</em>, and <em>The New York Times</em> Style section, 2022 through 2026.</li>
      <li>Wilding, J. P. H., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." <em>New England Journal of Medicine</em> 384: 989–1002.</li>
      <li>Jastreboff, A. M., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." <em>New England Journal of Medicine</em> 387: 205–216.</li>
      <li>Walker, R. F. (2006). "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" <em>Clinical Interventions in Aging</em> 1(4): 307–308.</li>
      <li>Pizzorno, J. (2014). "Glutathione!" <em>Integrative Medicine: A Clinician's Journal</em> 13(1): 8–12.</li>
      <li>Sonthalia, S., Daulatabad, D., &amp; Sarkar, R. (2016). "Glutathione as a skin whitening agent: Facts, myths, evidence and controversies." <em>Indian Journal of Dermatology, Venereology and Leprology</em> 82(3): 262–272.</li>
      <li>Yoshino, J., Baur, J. A., &amp; Imai, S. (2018). "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." <em>Cell Metabolism</em> 27(3): 513–528.</li>
      <li>Verdin, E. (2015). "NAD+ in aging, metabolism, and neurodegeneration." <em>Science</em> 350(6265): 1208–1213.</li>
    </ol>
  </div>
</section>

The Ozempic body headlines barely scratch the surface. Glutathione, NAD+, and sermorelin are quietly rewriting Hollywood's relationship with aging, recovery, and red-carpet prep.

Hollywood's Worst-Kept Secret

<section class="hero">
  <div class="container">
    <div class="category">The Pru Series</div>
    <h1><em>Cost-Plus,</em><br>Explained</h1>
    <p class="dek">How <span class="brand-mark">pru</span> prices a vial. The wholesale cost, the markup, and exactly why each number is what it is.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 3-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Most telehealth brands tell you what their products cost. They do not tell you why. The price on the page is a single number with no breakdown, no source attribution, and no way to verify whether you are paying for medicine, advertising, or something else entirely.</p>

    <p><span class="brand-mark">pru</span> is built differently. We publish the math. Every component of the price you pay is broken out, named, and explained. The pharmacy cost. The syringe kit. The shipping. The physician's consult. The platform overhead. The margin we keep. None of it is hidden, because none of it should be.</p>

    <h2>The formula</h2>

    <p>Pharmacy cost plus a flat fifteen percent margin. That is our entire pricing rule for members. Whatever the wholesale cost of the molecule and the supplies that come with it, we add a small markup to keep the lights on, and we tell you what every line item is. The fifteen percent is not a marketing number. It is the number that lets us pay engineers, clinicians, and customer support without hiding fees inside the price of medicine.</p>

    <h2>A worked example: Tirzepatide</h2>

    <p>Here is the math on a real prescription from the <span class="brand-mark">pru</span> formulary. <strong>Tirzepatide injectable</strong>, two milliliters at sixteen-point-six milligrams per milliliter — thirty-three-point-two milligrams of medicine in the bottle. The structure is the same for every peptide we offer. The numbers change with the molecule, the dose, and the supplies it requires.</p>

    
    <div class="breakdown">
      <div class="breakdown-eyebrow">Worked Example · Tirzepatide</div>
      <div class="breakdown-title">How we get to $165.60</div>
      <div class="breakdown-subhead">Tirzepatide injectable · 2 mL · 33.2 mg</div>

      <div class="line-item">
        <div class="line-content">
          <div class="line-label">Pharmacy cost</div>
          <div class="line-desc">From the FDA-regulated 503A compounding pharmacy that prepares your peptide.</div>
        </div>
        <div class="line-amount">$75.00</div>
      </div>

      <div class="line-item">
        <div class="line-content">
          <div class="line-label">Syringe kit</div>
          <div class="line-desc">Sterile single-use injection kit, included with every injectable.</div>
        </div>
        <div class="line-amount">$5.00</div>
      </div>

      <div class="line-item">
        <div class="line-content">
          <div class="line-label">Shipping</div>
          <div class="line-desc">Cold-chain delivery direct to your door.</div>
        </div>
        <div class="line-amount">$20.00</div>
      </div>

      <div class="line-item">
        <div class="line-content">
          <div class="line-label">Physician consult</div>
          <div class="line-desc">Independent licensed M.D. who reviews your health profile and writes the prescription.</div>
        </div>
        <div class="line-amount">$20.00</div>
      </div>

      <div class="line-item">
        <div class="line-content">
          <div class="line-label">Marketing &amp; platform</div>
          <div class="line-desc">A flat 20% to keep the lights on. Engineering, support, content, payroll.</div>
        </div>
        <div class="line-amount">$24.00</div>
      </div>

      <div class="subtotal-row">
        <div class="subtotal-label">Cost basis</div>
        <div class="subtotal-amount">$144.00</div>
      </div>

      <div class="line-item" style="border-bottom: none;">
        <div class="line-content">
          <div class="line-label"><span class="brand-mark">pru</span> margin</div>
          <div class="line-desc">15% of cost. Our entire profit on the bottle.</div>
        </div>
        <div class="line-amount add">+ $21.60</div>
      </div>

      <div class="total-row">
        <div class="total-label">You pay</div>
        <div class="total-amount">$165.60</div>
      </div>
    </div>

    <h2>Why we do it this way</h2>

    <p>Most telehealth brands quote one number. They cannot tell you what fraction of that number is the medicine, what fraction is the marketing, or what fraction is the founder's salary.</p>

    <p>We chose the opposite approach. The breakdown is a feature, not a marketing trick. If our pharmacy cost goes up, your price goes up by the same dollar amount. If we negotiate a better wholesale rate, your price comes down. There is no surprise.</p>

    
    <div class="compare">
      <div class="compare-eyebrow">The same molecule, the difference is the markup</div>
      <div class="compare-grid">
        <div class="compare-card brand-card">
          <div class="compare-tag"><span class="brand-mark">pru</span> Member</div>
          <div class="compare-price">$165</div>
          <div class="compare-note">Cost-plus pricing, every line item published.</div>
        </div>
        <div class="compare-card">
          <div class="compare-tag">Industry Average</div>
          <div class="compare-price">~$450</div>
          <div class="compare-note">Single sticker price, no breakdown, no verification.</div>
        </div>
      </div>
      <div class="compare-fineprint">Industry comparison reflects publicly listed prices for compounded Tirzepatide across other U.S. telehealth brands. Pricing varies by brand, dose, and time.</div>
    </div>

    
    <div class="pullquote">
      <p>The breakdown is a <span class="mark">feature</span>, not a marketing trick.</p>
    </div>

    <h2>What membership covers</h2>

    <p><span class="brand-mark">pru</span> membership is fifty dollars a month. It is the only membership we sell, and it covers the things that recurring care actually requires.</p>

    
    <div class="membership">
      <div class="membership-head">
        <div class="membership-title">The <span class="brand-mark">pru</span> Membership</div>
        <div class="membership-price">$50<small>/month</small></div>
      </div>
      <ul>
        <li><strong>Industry-low pricing</strong> on every prescribed peptide. Members pay our 15% margin instead of the typical industry markup. On most protocols, the savings on your first order alone exceed a full month of membership. Every order after that adds more savings.</li>
        <li><strong>Unlimited physician messaging</strong> during your active protocol. Direct line to your prescribing physician, no extra charge.</li>
        <li><strong>25% off every future consult.</strong> Whether you are being prescribed something new or booking a synchronous follow-up to track progress, the member rate applies.</li>
        <li><strong>Priority refill coordination.</strong> We coordinate refill timing with your physician seven days before your current supply runs out, so there is no protocol gap.</li>
        <li><strong>The <span class="brand-mark">pru</span> Brief, members' edition.</strong> Quarterly research digest, member case stories, and an early subscriber preview of new compounds we add to the catalog.</li>
      </ul>
    </div>

    <h2>The principle</h2>

    <p>Cost-plus pricing is unusual in this industry. We think it should not be. The medicine you take should be priced the way every other professional service is priced: cost of materials, cost of labor, a stated margin, and an itemized bill. That is what trust looks like in healthcare. It is what we are committed to delivering.</p>

  </div>
</article>

How pru prices a vial. The wholesale cost, the markup, and exactly why each number is what it is.

Cost-Plus, Explained

<section class="hero">
  <div class="container">
    <div class="category">The Science Series</div>
    <h1>The Coenzyme<br>That <em>Runs Out</em></h1>
    <p class="dek">NAD+ powers the chemistry that keeps you alive, and your supply quietly collapses in your 40s. Injectable replacement has become longevity's most-asked-about therapy.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">NAD+ is not a name most people recognize. It does not get talked about on cable news. It is not in the supplement aisle next to vitamin C. But every cell in your body uses it. Without it, your mitochondria stop working, your DNA repair stops working, your basic energy chemistry stops working, and you stop working.</p>

    <p>That should be the end of the story. Your body makes NAD+. Your body uses NAD+. The system runs. Except it does not, exactly. Sometime in your forties, your NAD+ levels begin to fall. By the time you are seventy, the levels in many tissues are roughly half what they were at twenty. The reasons are still being worked out. The trend is well-documented. And it is the reason injectable NAD+ has become one of the most-asked-about therapies in longevity medicine.</p>

    <h2>What NAD+ actually does</h2>

    <p>NAD+ stands for <em>nicotinamide adenine dinucleotide</em>. It is a small molecule, a coenzyme, found in every living cell. It exists in two forms: an oxidized form, called NAD+, and a reduced form, called NADH. The cell flips it back and forth as part of the chemical reactions that produce energy.</p>

    <p>In the simplest terms, NAD+ is how your cells move electrons. Every food molecule you eat is broken down through a series of reactions. Many of those reactions transfer electrons. NAD+ accepts the electrons (becoming NADH). NADH then carries them to the mitochondria, where they are used to generate ATP, the body's energy currency. Without NAD+, the entire chain of reactions that turns food into useable energy stops.</p>

    <p>That is only the metabolism side. NAD+ also acts as a substrate for several other classes of enzymes that govern DNA repair, gene expression, mitochondrial maintenance, and the cellular stress response. Different enzymes, different jobs, same molecule.</p>

    <h2>The decline</h2>

    <p>Cellular NAD+ levels are not stable across a lifespan. They drop. Studies in human tissues, including skin, liver, and skeletal muscle, have documented age-related decline. The exact magnitude varies by tissue and by which form of NAD is measured, but the pattern is consistent. Younger tissues have more NAD+. Older tissues have less.</p>

    <p>The mechanisms that drive the decline are not fully resolved, but the leading candidates are clear. One is increased activity of an enzyme called CD38, which consumes NAD+ at higher rates as immune cells become more active with age. Another is the accumulated DNA damage of normal living, which activates PARP enzymes that consume NAD+ as they repair the damage. A third is reduced synthesis of NAD+ from its dietary precursors. Aging, in this view, is partly a story of NAD+ being burned faster than it can be made.</p>

    
    <div class="chart-wrap">
      <svg viewBox="0 0 680 280" xmlns="http://www.w3.org/2000/svg" aria-label="Generalized trend of declining NAD+ levels with age, based on cross-sectional human tissue studies">

        
        <line x1="80" y1="60" x2="80" y2="220" stroke="#e8dcc4" stroke-width="1"></line>

        
        <line x1="80" y1="220" x2="620" y2="220" stroke="#e8dcc4" stroke-width="1"></line>

        
        <line x1="80" y1="140" x2="620" y2="140" stroke="#e8dcc4" stroke-width="1" stroke-dasharray="3,3"></line>

        
        <text x="70" y="64" text-anchor="end" font-family="Inter, sans-serif" font-size="10" fill="#786a60" font-weight="600">100%</text>
        <text x="70" y="144" text-anchor="end" font-family="Inter, sans-serif" font-size="10" fill="#786a60" font-weight="600">50%</text>
        <text x="70" y="224" text-anchor="end" font-family="Inter, sans-serif" font-size="10" fill="#786a60" font-weight="600">0%</text>

        
        <text x="32" y="140" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#786a60" font-weight="600" letter-spacing="1.5" transform="rotate(-90 32 140)">RELATIVE NAD+ LEVEL</text>

        
        <text x="80" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">20</text>
        <text x="170" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">30</text>
        <text x="260" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">40</text>
        <text x="350" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">50</text>
        <text x="440" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">60</text>
        <text x="530" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">70</text>
        <text x="620" y="240" text-anchor="middle" font-family="Inter, sans-serif" font-size="11" fill="#4a423d" font-weight="500">80</text>

        
        <text x="350" y="264" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#786a60" font-weight="600" letter-spacing="2">AGE IN YEARS</text>

        
        <text x="260" y="44" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="14" font-style="italic" fill="#730e07">decline accelerates</text>
        <line x1="260" y1="50" x2="260" y2="80" stroke="#730e07" stroke-width="0.5" stroke-dasharray="2,2"></line>

        
        <polyline points="80,60 170,68 260,84 350,108 440,124 530,137 620,143" stroke="#730e07" stroke-width="2.5" fill="none"></polyline>

        
        <circle cx="80" cy="60" r="4.5" fill="#730e07"></circle>
        <circle cx="170" cy="68" r="4.5" fill="#730e07"></circle>
        <circle cx="260" cy="84" r="4.5" fill="#730e07"></circle>
        <circle cx="350" cy="108" r="4.5" fill="#730e07"></circle>
        <circle cx="440" cy="124" r="4.5" fill="#730e07"></circle>
        <circle cx="530" cy="137" r="4.5" fill="#730e07"></circle>
        <circle cx="620" cy="143" r="4.5" fill="#730e07"></circle>
      </svg>
      <div class="chart-caption">Generalized trend, NAD+ levels by age</div>
      <div class="chart-source">Directional curve based on cross-sectional human tissue studies. Magnitude varies by tissue, sex, and assay (Massudi et al., 2012; Yoshino et al., 2018; Verdin, 2015).</div>
    </div>

    <h2>Why this matters for the rest of the body</h2>

    <p>Falling NAD+ has cellular consequences. Mitochondrial function declines because the redox cycling slows. Sirtuin activity falls, because sirtuins require NAD+ to function. DNA damage accumulates, because the repair enzymes that fix it are competing with sirtuins for the same shrinking pool. Each of these changes maps onto features of biological aging that have been documented for decades, including loss of muscle quality, declining metabolic flexibility, and reduced exercise tolerance.</p>

    <p>This is why NAD+ has attracted the attention it has. The hypothesis, supported by a growing experimental literature, is that restoring cellular NAD+ levels can slow or partially reverse some of the age-related decline in cellular function.</p>

    
    <div class="functions-wrap">
      <div class="functions-header">Where NAD+ goes inside the cell</div>
      <div class="functions-grid">

        <div class="function-card">
          <div class="function-num">I</div>
          <div class="function-name">Metabolism</div>
          <div class="function-title">Powering ATP production</div>
          <p>NAD+ and NADH cycle continuously in mitochondria to convert food into ATP, the body's energy currency.</p>
        </div>

        <div class="function-card">
          <div class="function-num">II</div>
          <div class="function-name">Sirtuins</div>
          <div class="function-title">Longevity proteins</div>
          <p>Seven sirtuin enzymes (SIRT1 through SIRT7) require NAD+ to regulate DNA repair, gene expression, and mitochondrial maintenance.</p>
        </div>

        <div class="function-card">
          <div class="function-num">III</div>
          <div class="function-name">PARPs</div>
          <div class="function-title">DNA damage repair</div>
          <p>PARP enzymes use NAD+ to repair the DNA breaks that accumulate from radiation, chemicals, and the byproducts of normal metabolism.</p>
        </div>

        <div class="function-card">
          <div class="function-num">IV</div>
          <div class="function-name">CD38</div>
          <div class="function-title">Immune signaling</div>
          <p>CD38 is the major consumer of NAD+ in immune cells. Its activity rises with age, accelerating NAD+ depletion in older tissues.</p>
        </div>

      </div>
    </div>

    <h2>How it gets replaced</h2>

    <p>Three approaches have emerged for raising NAD+ in the body. The first is dietary precursors: niacin (vitamin B3), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). These are taken as oral supplements and are converted to NAD+ inside cells. Human trials have shown that NR and NMN can raise blood NAD+ levels, though the magnitude and durability vary across studies.</p>

    <p>The second approach is direct injection or intravenous infusion of NAD+. This is what most longevity-clinic protocols use. The molecule is administered as a compounded preparation, often by subcutaneous injection or by IV. The pharmacokinetics differ from oral precursors: blood levels rise faster, and the dose can be controlled precisely.</p>

    <p>The third approach is to slow the consumption of NAD+, primarily by inhibiting CD38. This is the most experimental of the three strategies, with most data still coming from animal studies.</p>

    
    <div class="pullquote">
      <p>Aging, in this view, is partly a story of NAD+ being <span class="mark">burned faster</span> than it can be made.</p>
    </div>

    <h2>Why injectable</h2>

    <p>For most patients, the choice between oral and injectable NAD+ is not theoretical. It is a question of bioavailability and dosing. Oral precursors are convenient and inexpensive but rely on the body's own enzymes to convert them, and the conversion can be partial. Injectable NAD+ skips the conversion entirely. The molecule that the cell uses is the molecule that arrives. This is why the longevity-medicine community has increasingly converged on injection as the preferred route for patients who want measurable changes in tissue NAD+ levels.</p>

    <p>The trade-off is that injectable NAD+ has to be sourced from a state-licensed compounding pharmacy. There is no over-the-counter version. The 503A compounding infrastructure that has matured over the last decade is what makes the injectable option practical for individual patients.</p>

    <h2>What we know and what we don't</h2>

    <p>The science of NAD+ has matured rapidly. The decline with age is well-documented. The metabolic role is settled. The sirtuin connection is established. What is less settled is the size of the clinical effect from NAD+ replacement in healthy adults, and how long it lasts. Several human trials are underway. The early signals are encouraging but not yet definitive at the scale of the GLP-1 trials.</p>

    <p>This is the honest middle: NAD+ is a real molecule with a real cellular role that really does decline with age. The therapy that follows is supported by the biology and is being characterized clinically. The frontier is mature enough to be safe and tested, and not yet mature enough to make breathless promises.</p>

    <h2>Where pru sits in the NAD+ conversation</h2>

    <p>At <span class="brand-mark">pru</span>, NAD+ is one of the longevity therapies on our formulary because the science is strong enough to defend and the patient experience is well-characterized enough to deliver responsibly. The molecule is compounded at a 503A licensed pharmacy. Each batch ships with a Certificate of Analysis. The dose is matched to the patient.</p>

    <p>The chemistry that has been keeping you alive since you were born can be supported, when the body's supply begins to fall, by the same molecule the body has always used. That is what responsible longevity medicine looks like. It is what we are committed to delivering.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>Massudi, H., Grant, R., Braidy, N., et al. (2012). "Age-Associated Changes in Oxidative Stress and NAD+ Metabolism in Human Tissue." <em>PLoS ONE</em> 7(7): e42357.</li>
      <li>Yoshino, J., Baur, J. A., &amp; Imai, S. (2018). "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." <em>Cell Metabolism</em> 27(3): 513–528.</li>
      <li>Verdin, E. (2015). "NAD+ in aging, metabolism, and neurodegeneration." <em>Science</em> 350(6265): 1208–1213.</li>
      <li>Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., et al. (2016). "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction Through an SIRT3-Dependent Mechanism." <em>Cell Metabolism</em> 23(6): 1127–1139.</li>
      <li>Imai, S., &amp; Guarente, L. (2014). "NAD+ and sirtuins in aging and disease." <em>Trends in Cell Biology</em> 24(8): 464–471.</li>
      <li>Rajman, L., Chwalek, K., &amp; Sinclair, D. A. (2018). "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." <em>Cell Metabolism</em> 27(3): 529–547.</li>
      <li>Martens, C. R., Denman, B. A., Mazzo, M. R., et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." <em>Nature Communications</em> 9: 1286.</li>
      <li>Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." <em>Science</em> 372(6547): 1224–1229.</li>
      <li>Bonkowski, M. S., &amp; Sinclair, D. A. (2016). "Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds." <em>Nature Reviews Molecular Cell Biology</em> 17(11): 679–690.</li>
    </ol>
  </div>
</section>

NAD+ powers the chemistry that keeps you alive, and your supply quietly collapses in your 40s. Injectable replacement has become longevity's most-asked-about therapy.

The Coenzyme That Runs Out

Follow a single peptide molecule from your injection site to the cellular receptor it was designed to find, and what happens in the seconds after it locks on.

From Vial to Receptor

<section class="hero">
  <div class="container">
    <div class="category">The Regulatory Series</div>
    <h1><em>503A</em> vs <em>503B</em></h1>
    <p class="dek">Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Walk into a CVS in any city and ask for a vial of semaglutide compounded for your specific dose. You will be told, with some bewilderment, that they do not do that. They cannot do that. The chemistry is straightforward. The reason it cannot happen at a chain pharmacy is not chemistry. It is law.</p>

    <p>Two sections of the Federal Food, Drug, and Cosmetic Act, written years apart and forced to grow up by an outbreak that killed sixty-four people, decide where your peptide can be made and who is allowed to make it. They are called Section 503A and Section 503B. Together they describe the entire universe of compounded medications in the United States. Together they decide whether the peptide in your refrigerator is medicine or something else.</p>

    <h2>What "compounding" actually means</h2>

    <p>A compounded drug is a medication prepared for a specific patient by a licensed pharmacy, usually because the manufactured version does not exist or does not meet that patient's needs. A child who cannot swallow a tablet might need the drug in liquid form. A patient allergic to a dye in a commercial product might need a dye-free version. A peptide therapy, dosed precisely for one patient and not produced as a finished commercial drug, is compounded.</p>

    <p>This is an old practice. American pharmacy was almost entirely compounding until industrial pharmaceutical manufacturing took over in the twentieth century. What modern law had to do was draw clear lines around it: who can compound, for whom, at what scale, and to what standards. Section 503A and Section 503B are those lines.</p>

    <h2>1997, 2012, 2013</h2>

    <p>The first formal compounding framework was the FDA Modernization Act of 1997. It carved out an exemption from full drug-manufacturer regulation for pharmacies that compounded individual prescriptions. That exemption became Section 503A. For the next fifteen years, it described essentially all of legitimate compounding in the United States.</p>

    <p>In 2012, a Massachusetts pharmacy called the New England Compounding Center shipped contaminated methylprednisolone injections to clinics in twenty-three states. Sixty-four patients died from fungal meningitis. Seven hundred and ninety-three more became seriously ill. The pharmacy's owner was eventually convicted on federal charges. The outbreak made it clear that 503A had been written for a smaller world, one in which compounding pharmacies prepared individual prescriptions rather than industrial-scale batches shipped in bulk.</p>

    <p>Congress responded the next year with the Drug Quality and Security Act of 2013. The law added a second category, Section 503B, for facilities that compound at scale without patient-specific prescriptions. The two sections, taken together, became the law that governs every legitimate compounded vial in the country.</p>

    
    <div class="timeline-wrap">
      <svg viewBox="0 0 680 220" xmlns="http://www.w3.org/2000/svg" aria-label="The regulatory history of compounded drugs in the United States">
        
        <line x1="60" y1="100" x2="620" y2="100" stroke="#730e07" stroke-width="1" opacity="0.5"></line>

        
        <g>
          <circle cx="60" cy="100" r="6" fill="#730e07"></circle>
          <text x="60" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1997</text>
          <text x="60" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">FDAMA</text>
          <text x="60" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Section 503A</text>
          <text x="60" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">established</text>
        </g>

        
        <g>
          <circle cx="246" cy="100" r="6" fill="#730e07"></circle>
          <text x="246" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">2012</text>
          <text x="246" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">NECC OUTBREAK</text>
          <text x="246" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">64 deaths,</text>
          <text x="246" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">23 states</text>
        </g>

        
        <g>
          <circle cx="434" cy="100" r="6" fill="#730e07"></circle>
          <text x="434" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">2013</text>
          <text x="434" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="600">DQSA</text>
          <text x="434" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Section 503B</text>
          <text x="434" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">established</text>
        </g>

        
        <g>
          <circle cx="620" cy="100" r="8" fill="#730e07" stroke="#faf6f0" stroke-width="2"></circle>
          <circle cx="620" cy="100" r="14" fill="none" stroke="#730e07" stroke-width="1" opacity="0.4"></circle>
          <text x="620" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="600" fill="#730e07">Today</text>
          <text x="620" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">TWO-TIER</text>
          <text x="620" y="144" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">compounding</text>
          <text x="620" y="160" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">framework</text>
        </g>
      </svg>
      <div class="timeline-caption">How the framework arrived at its current shape</div>
    </div>

    <h2>503A: the patient-specific compounder</h2>

    <p>A 503A pharmacy compounds medications for individual named patients with valid prescriptions. Every vial leaving the pharmacy carries a prescription label showing the patient's name, the prescriber, the dose, and the expiration date. State boards of pharmacy regulate 503A pharmacies as their primary oversight body. The FDA also has authority, especially when interstate shipping crosses certain volume thresholds, but day-to-day inspection happens at the state level.</p>

    <p>Sterile compounded products, including all injectable peptides, must be made under USP General Chapter 797, which sets requirements for cleanroom design, air-quality testing, sterilization, personnel training, and final-product release. Each batch is documented. Each prescription is filled against a specific patient's record. This is where the great majority of compounded peptides for individual patients come from in the United States.</p>

    <h2>503B: the outsourcing facility</h2>

    <p>A 503B facility, formally called an outsourcing facility, compounds at scale without patient-specific prescriptions. The customer is typically a clinic or hospital that needs office-stock supply rather than a single named patient. To make this legal, 503B facilities must operate under Current Good Manufacturing Practice standards, the same framework used by industrial pharmaceutical manufacturers. They are inspected by the FDA directly, on a published schedule, the way a manufacturer is inspected.</p>

    <p>503B facilities can ship interstate without the volume limits that apply to 503A pharmacies. They register voluntarily with the FDA and submit production reports. The standards are higher, the federal oversight is more direct, and the volume per facility is much larger.</p>

    
    <div class="comparison">
      <div class="comparison-header">Side by side</div>
      <div class="comp-grid">
        <div class="comp-card">
          <div class="comp-num">503A</div>
          <div class="comp-tagline">Patient-Specific</div>
          <div class="comp-row">
            <div class="comp-label">Who it serves</div>
            <div class="comp-value">An individual patient with a valid prescription written for that patient.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Standards</div>
            <div class="comp-value">USP General Chapter 797 for sterile, 795 for non-sterile preparations.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Primary regulator</div>
            <div class="comp-value">State board of pharmacy, with FDA authority above certain thresholds.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Typical use</div>
            <div class="comp-value">Personalized peptide therapy, custom dosing, allergy-driven reformulation.</div>
          </div>
        </div>
        <div class="comp-card">
          <div class="comp-num">503B</div>
          <div class="comp-tagline">Outsourcing Facility</div>
          <div class="comp-row">
            <div class="comp-label">Who it serves</div>
            <div class="comp-value">Clinics and hospitals that need office stock, without patient-specific prescriptions.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Standards</div>
            <div class="comp-value">Current Good Manufacturing Practice (CGMP), the same standard as a drug manufacturer.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Primary regulator</div>
            <div class="comp-value">FDA, directly, with scheduled inspections and production reporting.</div>
          </div>
          <div class="comp-row">
            <div class="comp-label">Typical use</div>
            <div class="comp-value">Bulk office stock, in-clinic injectables, surgical-suite preparations.</div>
          </div>
        </div>
      </div>
    </div>

    <h2>Why the distinction matters for your prescription</h2>

    <p>Two practical things follow from this legal architecture. First, your peptide prescription has to be written specifically for you, by a licensed clinician, to be filled at a 503A pharmacy. There is no "self-prescribed" route, and the absence of a prescription is what legally distinguishes a compounded medication from a "research grade" chemical. Second, the pharmacy that fills your prescription has a name, a license, an inspection record, and a state board accountable for its conduct. Any of this can be audited if you want to.</p>

    <p>Both of these are features, not friction. They are the reason a compounded peptide is treated as medicine and the reason your name is on the label.</p>

    
    <div class="pullquote">
      <p>The two short numbers, <span class="mark">503A</span> and <span class="mark">503B</span>, are the entire architecture of legitimate compounded medicine in the United States.</p>
    </div>

    <h2>Where pru sits in this framework</h2>

    <p>At <span class="brand-mark">pru</span>, every prescription is filled at a state-licensed 503A pharmacy that we have evaluated in detail. The pharmacy has a name. The pharmacy has a license number. The pharmacy is inspected by its state board. Each batch ships with a Certificate of Analysis. We chose 503A as the framework for individual patient prescriptions because that is what the law was designed for, and because the level of patient-specific care it requires is the level we want delivered to every <span class="brand-mark">pru</span> patient.</p>

    <p>The two short numbers are the entire architecture. They explain why CVS does not sell peptides, why your prescription has to be written a specific way, and why the pharmacy filling it is named, licensed, and accountable. The next time you read a vial label, those numbers are the reason it says what it says.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>U.S. Food and Drug Administration. <em>Compounding and the FDA: Questions and Answers.</em> fda.gov/drugs/human-drug-compounding.</li>
      <li>Drug Quality and Security Act of 2013. <em>Public Law 113-54.</em> Codified at 21 U.S.C. §§ 353a (Section 503A) and 353b (Section 503B).</li>
      <li>FDA Modernization Act of 1997. <em>Public Law 105-115.</em> Original statutory creation of the 503A compounding exemption.</li>
      <li>Smith, R. M., Schaefer, M. K., Kainer, M. A., et al. (2013). "Fungal Infections Associated with Contaminated Methylprednisolone Injections." <em>New England Journal of Medicine</em> 369: 1598–1609. (Canonical publication on the 2012 NECC outbreak.)</li>
      <li>United States Pharmacopeia. <em>General Chapter 797: Pharmaceutical Compounding, Sterile Preparations.</em> Current revision.</li>
      <li>United States Pharmacopeia. <em>General Chapter 795: Pharmaceutical Compounding, Non-sterile Preparations.</em> Current revision.</li>
      <li>U.S. Food and Drug Administration. <em>Registered Outsourcing Facilities (Section 503B).</em> fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.</li>
      <li>U.S. Food and Drug Administration. <em>Current Good Manufacturing Practice (CGMP) Regulations.</em> 21 CFR Parts 210 and 211.</li>
      <li>Centers for Disease Control and Prevention. <em>Multistate Fungal Meningitis Outbreak Investigation, 2012–2013.</em> cdc.gov.</li>
    </ol>
  </div>
</section>

Two short numbers in federal pharmacy law are the reason peptides come from compounders instead of CVS, and the reason your prescription has to be written a specific way to be filled at all.

503A vs 503B

<section class="hero">
  <div class="container">
    <div class="category">The Culture Series</div>
    <h1>Where <em>Andrew Huberman</em><br>Lands on Peptides</h1>
    <p class="dek">The Stanford neuroscientist's public positions on growth hormone secretagogues, GLP-1s, and longevity peptides, held up against the actual literature.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">For an enormous number of Americans, the first time they heard the word <em>peptide</em> was on the Huberman Lab podcast. Andrew Huberman is a tenured Associate Professor of Neurobiology and Ophthalmology at Stanford University School of Medicine, a researcher with a published lab record, and the host of one of the most popular science podcasts in the world. The combination of credentials and audience has given him a singular role in the contemporary peptide conversation.</p>

    <p>Anyone trying to understand that conversation has to reckon with where Huberman lands on it. The shorter version: he is interested, he is cautious, and he is consistent about pointing his listeners back to the published literature. That posture, more than any single take he has shared, is the most useful thing he has contributed to the public understanding of the field.</p>

    <h2>How Huberman frames peptides</h2>

    <p>Across his publicly available podcast episodes, Huberman applies a consistent framework when discussing peptide therapies. The framework can be summarized as four questions: What does the molecule do, mechanistically? What does the human evidence look like? What do we know about long-term safety? And what do we not know?</p>

    <p>This is the framework most clinicians use, and it produces what the responsible part of the field has been saying for years: peptide medicine is one of the most promising frontiers in biomedicine, and the rigor with which we use it has to match the promise. The Huberman commentary is not always the popular take. It is, in our view, the right one.</p>

    
    <div class="framework">
      <div class="framework-header">The four-question framework, paraphrased</div>
      <div class="framework-grid">
        <div class="framework-cell">
          <div class="framework-num">I</div>
          <div class="framework-q">What does it do, mechanistically?</div>
          <p>The receptor it binds, the cells it activates, and the response a clinician can predict in a real patient.</p>
        </div>
        <div class="framework-cell">
          <div class="framework-num">II</div>
          <div class="framework-q">What does the human evidence show?</div>
          <p>How large the effect is in actual patients, how long it lasts, and how it compares to doing nothing.</p>
        </div>
        <div class="framework-cell">
          <div class="framework-num">III</div>
          <div class="framework-q">What do we know about long-term safety?</div>
          <p>Outcomes measured in years rather than months. Heart, cancer, and hormonal balance: the endpoints that take time to read accurately.</p>
        </div>
        <div class="framework-cell">
          <div class="framework-num">IV</div>
          <div class="framework-q">What does the science still need to learn?</div>
          <p>The questions where the honest answer is "we are still finding out." Naming them is what separates rigor from guesswork.</p>
        </div>
      </div>
    </div>

    <h2>Growth hormone secretagogues</h2>

    <p>Growth hormone secretagogues, including sermorelin, CJC-1295, ipamorelin, and tesamorelin, do not deliver growth hormone directly. They tell the pituitary gland to make more of its own, in pulses that broadly resemble what your body produced when you were younger. The mechanism is the same one your body has used since it was built. The intervention is to ask the body to do something it already knows how to do.</p>

    <p>Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has a well-characterized safety database in that population. The others are used clinically off-label, with growing evidence and a longer human safety record forming each year. Huberman's commentary on this category lands where the literature does: real mechanism, plausible benefit, and an active frontier of clinical research that responsible practitioners are watching closely.</p>

    <h2>GLP-1 receptor agonists</h2>

    <p>On GLP-1 receptor agonists, semaglutide and tirzepatide, the framework yields its most confident answers, because the human evidence base is unusually strong. The STEP and SURMOUNT trial families, published in the <em>New England Journal of Medicine</em>, document mean weight loss of 14.9 percent for semaglutide at sixty-eight weeks and 20.9 percent for tirzepatide at seventy-two weeks. Side effects are documented. Side effects are tolerable for most patients. The drugs have already changed the trajectory of the obesity and diabetes epidemics in measurable ways.</p>

    <p>Where Huberman's commentary adds value to the public conversation is on the mechanism side, especially the role of GLP-1 in central nervous system regulation of appetite, which is an area of his own field. The science here is mature. The framework yields a clear and supportive read of the evidence.</p>

    <h2>BPC-157, the frontier case</h2>

    <p>BPC-157, sometimes referred to by the longer name <em>Body Protection Compound 157</em>, is the peptide most likely to come up in casual conversation about tissue repair. The animal evidence is genuinely promising. Healing accelerates. Tendons, gut tissue, and skin all respond. The mechanism involves angiogenesis (the formation of new blood vessels), and that mechanism is also why the field is taking the time to assemble the long-term human data before recommending it broadly. New blood-vessel formation is a feature in healing, and a question worth answering carefully for any cells that should not be growing.</p>

    <p>Huberman has discussed this thoughtfully in publicly available episodes. The version of the framework here is forward-looking: the science is promising, the human evidence is still arriving, and the discipline of waiting for it is what separates a serious clinical practice from a wellness storefront. This is exactly the kind of category <span class="brand-mark">pru</span> watches closely, with protocols ready to deploy on the day the evidence base meets the bar we set for our formulary.</p>

    
    <div class="peptide-comp">
      <div class="peptide-comp-header">Three categories, three different evidence bases</div>
      <div class="peptide-grid">
        <div class="pept-card">
          <div class="pept-cat">Category I</div>
          <div class="pept-name">GH Secretagogues</div>
          <div class="pept-row">
            <div class="pept-label">Molecules</div>
            <div class="pept-text">Sermorelin, CJC-1295, ipamorelin, tesamorelin</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Stimulate pituitary release of endogenous growth hormone.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Human Evidence</div>
            <div class="pept-evidence moderate">Moderate</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Open Question</div>
            <div class="pept-text">Long-term effects of sustained elevation in IGF-1.</div>
          </div>
        </div>

        <div class="pept-card">
          <div class="pept-cat">Category II</div>
          <div class="pept-name">GLP-1 Receptor Agonists</div>
          <div class="pept-row">
            <div class="pept-label">Molecules</div>
            <div class="pept-text">Semaglutide, tirzepatide</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Receptor agonism on GLP-1 (and GIP for tirzepatide).</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Human Evidence</div>
            <div class="pept-evidence">Strong</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Open Question</div>
            <div class="pept-text">Lean-mass preservation during rapid weight loss.</div>
          </div>
        </div>

        <div class="pept-card">
          <div class="pept-cat">Category III</div>
          <div class="pept-name">BPC-157</div>
          <div class="pept-row">
            <div class="pept-label">Molecules</div>
            <div class="pept-text">A synthetic peptide derived from a gastric protein.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Mechanism</div>
            <div class="pept-text">Promotes angiogenesis and tissue repair in animal models.</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Human Evidence</div>
            <div class="pept-evidence thin">Emerging</div>
          </div>
          <div class="pept-row">
            <div class="pept-label">Open Question</div>
            <div class="pept-text">Long-term human safety data on sustained angiogenesis.</div>
          </div>
        </div>
      </div>
    </div>

    
    <div class="pullquote">
      <p>Peptide medicine is one of the most promising frontiers in biomedicine. The <span class="mark">rigor</span> with which we use it has to match the promise.</p>
    </div>

    <h2>Where his commentary lands relative to the literature</h2>

    <p>For listeners, the practical takeaway from the Huberman canon on peptides is not a list of products. It is a posture: <em>understand what the evidence shows, act where it is strongest, and watch closely where it is still being written.</em> That posture is what responsible peptide medicine looks like, and it is the same posture <span class="brand-mark">pru</span> is built on.</p>

    <p>The peptide conversation is bigger than any one figure. But for an audience of millions, Huberman has been one of the most consistent public voices pushing the conversation toward primary sources. The rest of the field can either match that standard or fall behind it.</p>

    <p>At <span class="brand-mark">pru</span>, every therapy on our formulary is supported by peer-reviewed evidence and prescribed by a licensed clinician who can answer the four framework questions for the specific molecule, the specific dose, and the specific patient. We did not invent the science. Our job is to deliver it with the trust and transparency the science deserves, and to expand the formulary only when the evidence supports it. That is what the frontier of responsible peptide medicine looks like, and it is what we are committed to delivering.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>Stanford School of Medicine. <em>Huberman Laboratory.</em> hubermanlab.stanford.edu. (Faculty appointment and lab page.)</li>
      <li>Huberman Lab Podcast. hubermanlab.com. (Publicly available episode catalog covering peptides, longevity, and metabolic health.)</li>
      <li>Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." <em>New England Journal of Medicine</em> 384: 989–1002.</li>
      <li>Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." <em>New England Journal of Medicine</em> 387: 205–216.</li>
      <li>Falutz, J., Allas, S., Blot, K., et al. (2007). "Metabolic effects of a growth hormone-releasing factor in patients with HIV." <em>New England Journal of Medicine</em> 357: 2359–2370. (Tesamorelin pivotal trial.)</li>
      <li>Sigalos, J. T., &amp; Pastuszak, A. W. (2018). "The Safety and Efficacy of Growth Hormone-Releasing Peptides in Men." <em>Sexual Medicine Reviews</em> 6(1): 45–53.</li>
      <li>Sikiric, P., Seiwerth, S., Rucman, R., et al. (2014). "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." <em>Current Neuropharmacology</em> 12(2): 147–158.</li>
      <li>Drucker, D. J. (2018). "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." <em>Cell Metabolism</em> 27(4): 740–756.</li>
      <li>Bartke, A., List, E. O., &amp; Kopchick, J. J. (2016). "The somatotropic axis and aging: Benefits of endocrine defects." <em>Growth Hormone &amp; IGF Research</em> 27: 41–45. (Long-term IGF-1 elevation and longevity considerations.)</li>
    </ol>
  </div>
</section>

The Stanford neuroscientist's public positions on growth hormone secretagogues, GLP-1s, and longevity peptides, held up against the actual literature.

Where Andrew Huberman Lands on Peptides

<section class="hero">
  <div class="container">
    <div class="category">The Science Series</div>
    <h1>Why GLP-1 Works<br>When <em>Willpower</em> Doesn't</h1>
    <p class="dek">Semaglutide and tirzepatide rewire the brain's hunger signals at the receptor level: a quieter, more honest answer to why the GLP-1 era arrived so suddenly.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 5-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Most weight-loss advice ends with the same idea: try harder. Eat less. Move more. Use better discipline. The advice has been repeated so often that it has become the default explanation for why some people stay lean and others do not. The advice is also, in most cases, wrong about the biology.</p>

    <p>Hunger is not a feeling that floats around in your head, waiting for you to override it. It is a signal generated by hormones, sent to your brain, and processed by neurons that were tuned by evolution to make sure you do not starve. The signal has volume. The signal has duration. And the signal can be turned down.</p>

    <p>That is what GLP-1 receptor agonists do. They turn down the signal. Not by acting on willpower, which they cannot, but by acting at the level of the receptor where the hunger signal is heard.</p>

    <h2>What GLP-1 actually is</h2>

    <p>GLP-1 stands for <em>glucagon-like peptide 1</em>. It is a thirty-amino-acid peptide hormone your body makes throughout the day, mostly from L-cells lining your small intestine. When food arrives in the gut, those cells release GLP-1 into the bloodstream. The hormone reaches the pancreas, where it tells the pancreas to release insulin. It reaches the stomach, where it slows the rate at which the stomach empties. It reaches the brain, where it tells the brain that food has arrived and the meal can end.</p>

    <p>This is the system that decides, on your behalf, when you are full. You do not have to think about it. It runs whether you are paying attention or not. And in some bodies, for reasons that include genetics, age, prior dieting history, and chronic disease, the system runs at lower volume than is optimal. The signal to stop eating arrives quieter, later, or both.</p>

    <h2>How the drugs differ from your own GLP-1</h2>

    <p>Your own GLP-1 has a problem as a drug: it lasts about two minutes in the bloodstream before being broken down by an enzyme called DPP-4. To make a usable therapy, scientists modified the molecule. The changes were small but consequential. They added a few amino-acid substitutions and a fatty-acid tail that lets the modified peptide bind to albumin in the blood. The result was a peptide that acts on the same receptor as your own GLP-1 but lasts about a week instead of two minutes.</p>

    <p>Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for obesity, was the first such drug to reach broad use. Tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, goes one step further. It activates two receptors at once, GLP-1 and a related receptor called GIP. The dual action produces stronger effects on both blood sugar and body weight.</p>

    
    <div class="mechanism">
      <div class="mechanism-header">Where GLP-1 acts in the body</div>
      <div class="organ-grid">
        <div class="organ-card">
          <div class="organ-num">I</div>
          <div class="organ-name">Gut · L-cells</div>
          <div class="organ-title">Where it is made</div>
          <p>L-cells lining the small intestine release GLP-1 into the bloodstream after a meal arrives.</p>
        </div>
        <div class="organ-card">
          <div class="organ-num">II</div>
          <div class="organ-name">Pancreas</div>
          <div class="organ-title">The blood-sugar response</div>
          <p>Stimulates glucose-dependent insulin release and suppresses glucagon, lowering blood sugar.</p>
        </div>
        <div class="organ-card">
          <div class="organ-num">III</div>
          <div class="organ-name">Stomach</div>
          <div class="organ-title">Slowed gastric emptying</div>
          <p>Delays the rate at which food leaves the stomach, prolonging the sensation of fullness.</p>
        </div>
        <div class="organ-card">
          <div class="organ-num">IV</div>
          <div class="organ-name">Brain · Hypothalamus</div>
          <div class="organ-title">The satiety signal</div>
          <p>Activates POMC satiety neurons in the arcuate nucleus, generating fullness upstream of conscious thought.</p>
        </div>
      </div>
    </div>

    <h2>The brain mechanism, in detail</h2>

    <p>The brain mechanism is what makes GLP-1 receptor agonists feel different from older weight-loss drugs. Your hypothalamus is the region of your brain that regulates basic drives like hunger, thirst, and body temperature. Inside it, two opposing groups of neurons compete to set your appetite. One group, called POMC neurons, produces fullness when active. The other group, called AgRP neurons, produces hunger when active. GLP-1 receptors sit on the POMC neurons. When the receptor is activated by your own GLP-1 or by an injected analog like semaglutide, fullness is generated before you decide to think about it.</p>

    <p>Older weight-loss drugs worked by stimulating the central nervous system or by blocking fat absorption. They produced side effects that were often difficult to tolerate and benefits that were modest. GLP-1 receptor agonists work by mimicking a hormone the body already uses, on a circuit the body already runs. The drug does not invent new biology. It increases the volume on a signal that was already there.</p>

    <h2>What the clinical trials show</h2>

    <p>In the STEP 1 trial, published in the <em>New England Journal of Medicine</em> in 2021, adults with overweight or obesity who received weekly semaglutide for sixty-eight weeks lost on average 14.9 percent of their body weight. The placebo group lost 2.4 percent. The trial enrolled 1,961 patients.</p>

    <p>In SURMOUNT-1, published in the same journal in 2022, adults receiving the highest dose of tirzepatide lost on average 20.9 percent of their body weight at seventy-two weeks. The placebo group lost 3.1 percent. The trial enrolled 2,539 patients. The numbers are larger than what most weight-loss drugs have produced over the entire history of the drug class.</p>

    
    <div class="trials">
      <div class="trials-grid">
        <div class="trial-card">
          <div class="trial-label">STEP 1 · 2021</div>
          <div class="trial-drug">Semaglutide 2.4 mg, weekly</div>
          <div class="trial-stat">14.9%</div>
          <div class="trial-stat-label">Mean Body-Weight Loss</div>
          <div class="trial-bar">
            <div class="trial-bar-fill" style="width: 71.3%;"></div>
          </div>
          <div class="trial-meta">vs. <strong>2.4%</strong> on placebo<br>1,961 patients · 68 weeks</div>
          <div class="trial-cite">N Engl J Med 384 : 989–1002</div>
        </div>
        <div class="trial-card">
          <div class="trial-label">SURMOUNT-1 · 2022</div>
          <div class="trial-drug">Tirzepatide 15 mg, weekly</div>
          <div class="trial-stat">20.9%</div>
          <div class="trial-stat-label">Mean Body-Weight Loss</div>
          <div class="trial-bar">
            <div class="trial-bar-fill" style="width: 100%;"></div>
          </div>
          <div class="trial-meta">vs. <strong>3.1%</strong> on placebo<br>2,539 patients · 72 weeks</div>
          <div class="trial-cite">N Engl J Med 387 : 205–216</div>
        </div>
      </div>
    </div>

    
    <div class="pullquote">
      <p>GLP-1 receptor agonists do not work because they make people <span class="mark">stronger</span>. They work because they fix a signal.</p>
    </div>

    <h2>What this teaches us</h2>

    <p>For decades, the dominant cultural framing of body weight has been that fat people lack discipline. The framing has been moralized in advertising, in medicine, and in casual conversation. The framing has also failed, repeatedly, to predict outcomes. Diets work in the short term and fail in the long term. Patients regain weight even when they continue trying. The biology pulls them back.</p>

    <p>GLP-1 receptor agonists do not work because they make people stronger or more disciplined. They work because they correct a signal that, for many bodies, was running too quietly. The willpower framing was never describing the right system. The hormone was.</p>

    <p>Both semaglutide and tirzepatide are available through <span class="brand-mark">pru</span>, prescribed by a licensed clinician, compounded at a 503A licensed pharmacy, and accompanied by a Certificate of Analysis on every batch. The science is not ours. The standards we deliver it under are.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>Drucker, D. J. (2018). "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." <em>Cell Metabolism</em> 27(4): 740–756.</li>
      <li>Müller, T. D., Finan, B., Bloom, S. R., et al. (2019). "Glucagon-like peptide 1 (GLP-1)." <em>Molecular Metabolism</em> 30: 72–130.</li>
      <li>Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." <em>New England Journal of Medicine</em> 384: 989–1002.</li>
      <li>Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." <em>New England Journal of Medicine</em> 387: 205–216.</li>
      <li>Lau, J., Bloch, P., Schäffer, L., et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." <em>Journal of Medicinal Chemistry</em> 58(18): 7370–7380.</li>
      <li>Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." <em>Molecular Metabolism</em> 18: 3–14.</li>
      <li>Andermann, M. L., &amp; Lowell, B. B. (2017). "Toward a Wiring Diagram Understanding of Appetite Control." <em>Neuron</em> 95(4): 757–778. (POMC and AgRP neuron circuitry.)</li>
      <li>Secher, A., Jelsing, J., Baquero, A. F., et al. (2014). "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss." <em>Journal of Clinical Investigation</em> 124(10): 4473–4488.</li>
    </ol>
  </div>
</section>

Semaglutide and tirzepatide rewire the brain's hunger signals at the receptor level. A quieter, more honest answer to why the GLP-1 era arrived so suddenly.

Semaglutide and tirzepatide rewire the brain's hunger signals at the receptor level: a quieter, more honest answer to why the GLP-1 era arrived so suddenly.

Why GLP-1 Works When Willpower Doesn't

<section class="hero">
  <div class="container">
    <div class="category">The Foundations Series</div>
    <h1><span class="quote">"Research Grade"</span><br>Is Not What You Think</h1>
    <p class="dek">Two words on a vial label decide whether what you're injecting is medicine or an unregulated chemical. It's important you tell the difference.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 4-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Look at any peptide vial sold online. Buried in fine print, you will see one of two phrases. The first says <em>"For Research Use Only"</em> or <em>"Not For Human Consumption."</em> The second says nothing of the sort, because it is a prescription drug, dispensed from a licensed pharmacy.</p>

    <p>Those two phrases describe two completely different products, governed by two completely different sets of rules, made to two completely different standards. The molecules might share a name. Almost nothing else about them does.</p>

    
    <div class="twowords">
      <div class="twowords-label">The disclaimer that does the work</div>
      <div class="twowords-stamp">For Research Use Only · Not For Human Consumption</div>
    </div>

    <h2>What "research grade" actually means</h2>

    <p>The phrase <em>research grade</em> sounds technical and rigorous. In practice, it is the opposite. Under United States law, a substance labeled "for research use only" is not regulated as a drug by the FDA. The seller is making a legal claim: this is a chemical for laboratory experiments, not a medicine for people. That single claim does an enormous amount of work. It exempts the product from the testing, sterility, purity, and labeling rules that govern medicine.</p>

    <p>Translated: when you buy a vial labeled "research grade," you are buying something that has not been required to be tested for purity, sterility, identity, or dose. The seller is not required to verify that the peptide inside is what the label says it is. The seller is not required to ensure it is uncontaminated by bacteria, endotoxins, or unrelated chemicals. The seller is not required to make sure the dose is anything close to the labeled amount. None of those guarantees apply, because legally, it is not medicine.</p>

    <h2>What medical grade actually means</h2>

    <p>Medical-grade peptides come from a different world. They are compounded at a state-licensed 503A pharmacy under federal law passed in 2013, the Drug Quality and Security Act. Compounding pharmacies operate under USP General Chapter 797, which sets sterility standards for injectable preparations. Each batch is tested for identity (high-performance liquid chromatography and mass spectrometry), purity, sterility, and endotoxin levels. Each batch ships with a Certificate of Analysis showing those test results. Each prescription is filled against a written order from a licensed physician for a specific named patient.</p>

    <p>The pharmacy is inspected by both the state board of pharmacy and the FDA. The clinician carries a license. The patient has a chart. The vial has a chain of custody you can audit.</p>

    
    <div class="comparison">
      <div class="comparison-header">Side by side</div>
      <div class="comparison-grid">
        <div class="comp-col research">
          <div class="comp-title">Research Grade</div>
          <div class="comp-subtitle">Unregulated Chemical</div>
          <ul>
            <li>"For Research Use Only" disclaimer label</li>
            <li>No FDA oversight as a drug</li>
            <li>No required sterility testing</li>
            <li>No required identity verification</li>
            <li>No required purity testing</li>
            <li>No prescription required to purchase</li>
            <li>Anonymous online purchase</li>
            <li>No chain of custody</li>
          </ul>
        </div>
        <div class="comp-col medical">
          <div class="comp-title">Medical Grade</div>
          <div class="comp-subtitle">Compounded Prescription Drug</div>
          <ul>
            <li>Prescription label with patient name</li>
            <li>FDA and state pharmacy oversight</li>
            <li>USP 797 sterility standards</li>
            <li>HPLC and mass spectrometry verification</li>
            <li>Certificate of Analysis per batch</li>
            <li>Written prescription from a licensed clinician</li>
            <li>Named patient on file</li>
            <li>Documented chain of custody</li>
          </ul>
        </div>
      </div>
    </div>

    <h2>What that means in practice</h2>

    <p>Independent testing of black-market and gray-market peptides has documented wide variation in purity, identity, and contamination. Vials sold under one peptide name have been found to contain a different peptide entirely. Some show bacterial or endotoxin contamination at levels that would not be safe for injection. Some contain little or no active peptide at all. The buyer has no way to know which kind of vial is in their hand without sending it to a lab.</p>

    <p>Medical-grade peptides exist on the other side of a wall. Each batch's purity, identity, and sterility have been verified by testing before the vial leaves the pharmacy. Each Certificate of Analysis is auditable. Each pharmacy is inspected.</p>

    
    <div class="pullquote">
      <p>The molecules can be chemically <span class="mark">identical</span>. Everything around the molecule is what changes.</p>
    </div>

    <h2>How to tell the difference</h2>

    <p>You do not need a chemistry degree to read a vial. Three checks will tell you almost everything.</p>

    
    <div class="checklist">
      <div class="checklist-title">Three checks before you draw a dose</div>
      <div class="check-grid">
        <div class="check-item">
          <div class="check-num">1</div>
          <div class="check-heading">The label</div>
          <p>Does it have a prescription number, your name, an expiration date, and a licensed pharmacy address? If yes, medical grade. If the label says "Research Use Only," it is not.</p>
        </div>
        <div class="check-item">
          <div class="check-num">2</div>
          <div class="check-heading">The source</div>
          <p>Did a clinician evaluate your case and write a prescription, or did you click "add to cart" on a website that did not ask who you are? The former is medicine. The latter is not.</p>
        </div>
        <div class="check-item">
          <div class="check-num">3</div>
          <div class="check-heading">The documentation</div>
          <p>Is a Certificate of Analysis available? Can you trace the pharmacy that compounded the vial? If yes, medical grade. If no, treat the vial as unknown.</p>
        </div>
      </div>
    </div>

    <p>The peptide molecules themselves can be genuinely identical between the two grades. Synthesis chemistry does not care who is paying. What is different is everything around the molecule: who tested it, who certified it, who is liable if something goes wrong, who is legally allowed to sell it to you, and whether anyone has any incentive to make sure the vial in your hand is what the label says.</p>

    <p>That gap is not a technicality. It is the difference between a medicine and an experiment that you have agreed to run on yourself.</p>

    <p>Every therapy on the <span class="brand-mark">pru</span> formulary is medical grade. Each prescription is written by a licensed clinician. Each vial is compounded at a 503A pharmacy. Each batch ships with a Certificate of Analysis. We pay attention to the two words on the vial, because they are the two words that change everything else.</p>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>U.S. Food and Drug Administration. <em>Compounding and the FDA: Questions and Answers.</em> fda.gov/drugs/human-drug-compounding.</li>
      <li>Drug Quality and Security Act of 2013. <em>Public Law 113-54,</em> codified at 21 U.S.C. §§ 353a (503A) and 353b (503B).</li>
      <li>United States Pharmacopeia. <em>General Chapter 797: Pharmaceutical Compounding, Sterile Preparations.</em> Current revision.</li>
      <li>U.S. Food and Drug Administration. <em>Guidance for Industry: Investigational New Drug Applications and "Research Use Only" Labeling.</em> fda.gov.</li>
      <li>U.S. Food and Drug Administration. <em>Warning Letters and Untitled Letters to Vendors of Bulk Peptide Products Sold for Research Use.</em> fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.</li>
      <li>National Association of Boards of Pharmacy. <em>Compounding Pharmacy Inspection and Standards Resources.</em> nabp.pharmacy.</li>
      <li>U.S. Pharmacopeia. <em>Compounded Preparations: Identity, Strength, Quality, and Purity Standards.</em> usp.org.</li>
    </ol>
  </div>
</section>

Two words on a vial label decide whether what you're injecting is medicine or an unregulated chemical. Here is how to tell the difference.

Two words on a vial label decide whether what you're injecting is medicine or an unregulated chemical. It's important you tell the difference.

"Research Grade" Is Not What You Think

<section class="hero">
  <div class="container">
    <div class="category">The Pru Series</div>
    <h1>Why <span class="brand-mark">pru</span> Exists</h1>
    <p class="dek">Peptides changed lives before the system caught up to them. <span class="brand-mark">pru</span> is the company built to make sure the next generation of patients get them prescribed properly and transparently.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 4-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Some products reach the people they were built for. Others bounce around the wrong neighborhoods of the internet for fifteen years before anyone notices. Peptides are the second kind.</p>

    <p>For most of the last decade, the most clinically promising peptide therapies have been bought on shadowy research-chemical websites, mixed in apartment kitchens, and injected by people who did not know what was in the vial. The patients who needed them most were either getting nothing, or getting something dangerous. That is the world <span class="brand-mark">pru</span> was built to change.</p>

    <h2>What we saw</h2>

    <p>We started <span class="brand-mark">pru</span> after watching the same pattern play out, again and again. A patient hears about a peptide on a podcast, or from a doctor who works with athletes. They go looking. What they find is rarely what they need.</p>

    <p>The most common landing spots are three. The first is a clinic that costs eight thousand dollars a year and bundles peptides alongside testosterone, hair-loss pills, and skincare the patient never asked about. The second is a telehealth brand that lists forty different SKUs on its website but cannot tell you which compounding pharmacy made the vial in your hand. The third is a "research peptides" website that ships from overseas with disclaimers nobody reads, dosage calculators that nobody verifies, and quality controls that do not exist.</p>

    <p>Meanwhile, the science kept moving. Compounding pharmacies got cleaner. Clinical trials got bigger. The FDA went back and forth, and in February of this year, mostly forth. The case for medically supervised peptide therapy got stronger every quarter. The infrastructure to deliver it, properly, did not.</p>

    
    <div class="diagram-wrap">
      <svg viewBox="0 0 680 220" xmlns="http://www.w3.org/2000/svg" aria-label="The pru patient journey: four steps from consult to ongoing calibration">
        
        <line x1="60" y1="100" x2="600" y2="100" stroke="#730e07" stroke-width="1" opacity="0.5"></line>

        
        <g>
          <circle cx="60" cy="100" r="22" fill="#730e07"></circle>
          <text x="60" y="106" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#ffffff">1</text>
          <text x="60" y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="18" font-weight="500" fill="#1a1614">Consult</text>
          <text x="60" y="148" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Tell us</text>
          <text x="60" y="164" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">what you need</text>
        </g>

        
        <g>
          <circle cx="240" cy="100" r="22" fill="#730e07"></circle>
          <text x="240" y="106" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#ffffff">2</text>
          <text x="240" y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="18" font-weight="500" fill="#1a1614">Review</text>
          <text x="240" y="148" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">A licensed physician</text>
          <text x="240" y="164" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">evaluates your case</text>
        </g>

        
        <g>
          <circle cx="420" cy="100" r="22" fill="#730e07"></circle>
          <text x="420" y="106" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#ffffff">3</text>
          <text x="420" y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="18" font-weight="500" fill="#1a1614">Compound</text>
          <text x="420" y="148" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">A 503A pharmacy</text>
          <text x="420" y="164" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">fills your prescription</text>
        </g>

        
        <g>
          <circle cx="600" cy="100" r="22" fill="#730e07"></circle>
          <text x="600" y="106" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#ffffff">4</text>
          <circle cx="600" cy="100" r="32" fill="none" stroke="#730e07" stroke-width="1" opacity="0.4"></circle>
          <text x="600" y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="18" font-weight="600" fill="#730e07">Track &amp; Refine</text>
          <text x="600" y="148" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">Regular check-ins keep</text>
          <text x="600" y="164" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">your protocol calibrated</text>
        </g>
      </svg>
      <div class="diagram-caption">How a peptide reaches you, the <span class="brand-mark">pru</span> way</div>
    </div>

    <h2>What <span class="brand-mark">pru</span> is built on</h2>

    <p>Three commitments. They are simple to state and harder to keep. We staked the company on all three.</p>

    
    <div class="pillars-section">
      <div class="pillars-grid">
        <div class="pillar">
          <div class="pillar-numeral">I</div>
          <div class="pillar-name">Trust</div>
          <div class="pillar-tag">Licensed Clinicians &amp; 503A Pharmacies</div>
        </div>
        <div class="pillar">
          <div class="pillar-numeral">II</div>
          <div class="pillar-name">Transparency</div>
          <div class="pillar-tag">Cost-Plus, Visible</div>
        </div>
        <div class="pillar">
          <div class="pillar-numeral">III</div>
          <div class="pillar-name">Specialization</div>
          <div class="pillar-tag">Peptides Only</div>
        </div>
      </div>
      <div class="pillars-caption">The three commitments behind every prescription</div>
    </div>

    
    <div class="pillar-block">
      <div class="pillar-block-label">I &nbsp;·&nbsp; Trust</div>
      <div class="pillar-block-title">The doctor whose name is on your prescription is the doctor who decided you should have it.</div>
      <p>Every prescription on <span class="brand-mark">pru</span> is written by a licensed physician who reviewed your intake personally. We do not use auto-prescribers. After your first dose, your clinician is reachable, by name, for as long as you are a <span class="brand-mark">pru</span> patient. There is no extra fee for messages, follow-ups, or dosing questions, and there is no script that triages you to a different person each time.</p>
    </div>

    
    <div class="pillar-block">
      <div class="pillar-block-label">II &nbsp;·&nbsp; Transparency</div>
      <div class="pillar-block-title">Nothing in our business is hidden because nothing in it should be.</div>
      <p>We publish our cost-plus pricing model. The wholesale price of every vial, the markup we add on top, and where the rest of the money goes are visible to every patient. If the price ever changes, we will tell you why before you ask.</p>
    </div>

    
    <div class="pillar-block">
      <div class="pillar-block-label">III &nbsp;·&nbsp; Specialization</div>
      <div class="pillar-block-title">Six focus areas. That is the entire catalog.</div>
      <p><span class="brand-mark">pru</span> is built around six focus areas, all of them peptide and longevity therapies.</p>
      <div class="focus-areas">
        <span class="focus-area">Fat Loss &amp; Metabolism</span>
        <span class="focus-area">Cellular Health</span>
        <span class="focus-area">Muscle &amp; Performance</span>
        <span class="focus-area">Repair &amp; Regeneration</span>
        <span class="focus-area">Cognition &amp; Mood</span>
        <span class="focus-area">Sexual Health &amp; Intimacy</span>
      </div>
      <p>We do not sell testosterone, ED pills, hair loss, skin care, or anything outside that category. Our competitors sell a hundred different SKUs and master none of them. The peptide era deserves a brand that treats the category as the main event, not a sideline.</p>
    </div>

    <h2>What this looks like in practice</h2>

    <p>Pillars are easy to write. They are harder to operationalize. These are the operational guarantees that make ours real.</p>

    
    <div class="practice">
      <div class="practice-title">The <span class="brand-mark">pru</span> patient guarantee</div>
      <ul>
        <li><strong>Unlimited messaging</strong> with your clinician, with no extra fee for follow-ups, dosing questions, or check-ins.</li>
        <li><strong>Cost-plus pricing</strong> on every therapy, with the wholesale cost and markup published openly.</li>
        <li><strong>A 6 Category Formulary</strong>, with no SKU added unless we can defend it on medical merit.</li>
        <li><strong>A 503A licensed compounding pharmacy partner</strong>, fully audited, with a documented chain of custody.</li>
      </ul>
    </div>

    
    <div class="pullquote">
      <p>We are not the first company to sell peptides. We are trying to be the first to sell them the way they should have been sold from the <span class="mark">beginning</span>.</p>
    </div>

  </div>
</article>

The mission behind pru: trust, transparency, and a deliberate focus on peptide medicine, sold the way it should have been from the beginning.

Peptides changed lives before the system caught up to them. pru is the company built to make sure the next generation of patients get them prescribed properly and transparently.

Why pru Exists

<section class="hero">
  <div class="container">
    <div class="category">The Foundations Series</div>
    <h1>The Messenger<br>Molecules</h1>
    <p class="dek">Peptides without the jargon: a plain-English explanation of what they actually are, why your body already makes thousands of them, and why a small handful are reshaping modern medicine.</p>
    <svg class="ornament" viewBox="0 0 60 18" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
      <line x1="0" y1="9" x2="20" y2="9" stroke="#730e07" stroke-width="0.75"></line>
      <circle cx="30" cy="9" r="3" fill="#730e07"></circle>
      <line x1="40" y1="9" x2="60" y2="9" stroke="#730e07" stroke-width="0.75"></line>
    </svg>
    <div class="read-time">A 4-minute read</div>
  </div>
</section>

<article>
  <div class="container">

    <p class="lead">Right now, somewhere inside you, a tiny molecule is finding the exact cell it was built to talk to. It floats through your bloodstream past millions of other cells, ignores all of them, and locks onto a single receptor, the way a key fits into a single lock. Once it's there, it tells that cell to do something specific. Burn fat. Repair tissue. Feel hungry. Feel calm. Fall asleep.</p>

    <p>The molecule is called a peptide. Your body makes thousands of them, every day, your entire life, and a small handful of them are quietly reshaping modern medicine.</p>

    <h2>What a peptide actually is</h2>

    <p>A peptide is a chain of amino acids, the same twenty molecular building blocks that, in longer chains, make up every protein in your body. The difference between a peptide and a protein is mostly length. By chemistry's working convention, anything from two to roughly fifty amino acids is called a peptide; anything longer is usually called a protein. Insulin, with fifty-one amino acids in two linked chains, sits right on the border, which is why textbooks sometimes call it a "peptide hormone" and sometimes a "small protein."</p>

    <p>The reason length matters is that it determines what a molecule can physically do. Proteins are large, structural, and slow-moving. They form muscle fibers, antibodies, and the receptor sites on your cell surfaces. Peptides are smaller, faster, and built to carry messages between cells.</p>

    
    <div class="diagram-wrap">
      <svg viewBox="0 0 680 240" xmlns="http://www.w3.org/2000/svg" aria-label="Scale comparison: amino acid, peptide, protein">
        
        <g transform="translate(113, 100)">
          <circle r="14" fill="#730e07"></circle>
          <text y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">Amino acid</text>
          <text y="86" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#786a60" letter-spacing="2.4" font-weight="600">1 UNIT</text>
        </g>

        
        <g transform="translate(340, 100)">
          
          <path d="M -88 4 Q -68 -8 -54 0 Q -38 8 -22 -4 Q -6 -10 8 0 Q 22 8 38 -2 Q 54 -10 70 -2 Q 84 6 96 0" stroke="#730e07" stroke-width="1" fill="none" opacity="0.45"></path>
          <g fill="#730e07">
            <circle cx="-88" cy="4" r="7"></circle>
            <circle cx="-72" cy="-2" r="7"></circle>
            <circle cx="-54" cy="0" r="7"></circle>
            <circle cx="-38" cy="6" r="7"></circle>
            <circle cx="-22" cy="-4" r="7"></circle>
            <circle cx="-6" cy="-8" r="7"></circle>
            <circle cx="8" cy="0" r="7"></circle>
            <circle cx="22" cy="6" r="7"></circle>
            <circle cx="38" cy="-2" r="7"></circle>
            <circle cx="54" cy="-8" r="7"></circle>
            <circle cx="70" cy="-2" r="7"></circle>
            <circle cx="86" cy="4" r="7"></circle>
          </g>
          <text y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">Peptide</text>
          <text y="86" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#786a60" letter-spacing="2.4" font-weight="600">2 TO 50 UNITS</text>
        </g>

        
        <g transform="translate(567, 100)">
          
          <path d="M -38 -4
                   C -52 -22, -28 -38, -8 -28
                   C 14 -18, 30 -28, 36 -10
                   C 42 8, 22 22, 4 16
                   C -16 10, -32 22, -28 4
                   C -24 -10, -8 -14, 4 -6
                   C 18 4, 26 -2, 22 6" stroke="#730e07" stroke-width="3" fill="none" stroke-linecap="round" stroke-linejoin="round"></path>
          <text y="62" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">Protein</text>
          <text y="86" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#786a60" letter-spacing="2.4" font-weight="600">50+ UNITS</text>
        </g>
      </svg>
      <div class="diagram-caption">From building block to message to machine</div>
    </div>

    <h2>Your body already makes thousands of them</h2>

    <p>The human genome encodes roughly twenty thousand proteins. From those proteins, the body cleaves out a vast library of bioactive peptides. Thousands have been catalogued in scientific databases, with new ones still being discovered. Many of the words you already know are peptides:</p>

    
    <div class="callout">
      <div class="callout-title">Peptides You May Already Know</div>
      <div class="peptide-grid">
        <div class="peptide-card">
          <div class="peptide-name">Insulin</div>
          <div class="peptide-role">Controls blood sugar</div>
          <div class="peptide-aa">51 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">Oxytocin</div>
          <div class="peptide-role">Bonding, social trust, childbirth</div>
          <div class="peptide-aa">9 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">Vasopressin</div>
          <div class="peptide-role">Fluid balance, blood pressure</div>
          <div class="peptide-aa">9 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">Glucagon</div>
          <div class="peptide-role">Raises blood sugar</div>
          <div class="peptide-aa">29 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">GLP-1</div>
          <div class="peptide-role">The satiety hormone behind Ozempic &amp; Mounjaro</div>
          <div class="peptide-aa">30 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">Ghrelin</div>
          <div class="peptide-role">The hunger hormone</div>
          <div class="peptide-aa">28 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">GHRH</div>
          <div class="peptide-role">Tells the pituitary to release growth hormone</div>
          <div class="peptide-aa">44 amino acids</div>
        </div>
        <div class="peptide-card">
          <div class="peptide-name">Beta-endorphin</div>
          <div class="peptide-role">The body's painkiller</div>
          <div class="peptide-aa">31 amino acids</div>
        </div>
      </div>
    </div>

    <p>Each is a peptide your own body has made constantly since you were born. They are not foreign; they are not synthetic; they are not new to medicine. What is new is the ability to make them outside the body, purely, identically, at scale, and use them therapeutically.</p>

    <h2>Why a small handful are reshaping medicine</h2>

    <p>The first peptide drug was insulin, isolated from cattle pancreases in 1921 and given to a dying fourteen-year-old named Leonard Thompson in January 1922. He lived. The era of peptide medicine began with that single injection.</p>

    <p>For most of the next century, peptide drugs were rare and expensive. Synthesis was difficult; peptides degraded quickly in the bloodstream; they couldn't be taken as pills. Two breakthroughs changed that. The first was Bruce Merrifield's invention of solid-phase peptide synthesis in 1963, a way to manufacture peptides on a chemical scaffold, one amino acid at a time. He won the Nobel Prize for it in 1984. The second was the development of stabilization techniques that let modified peptides survive in the body long enough to actually work.</p>

    
    <div class="diagram-wrap">
      <svg viewBox="0 0 680 180" xmlns="http://www.w3.org/2000/svg" aria-label="A century of peptide medicine: timeline of milestones">
        
        <line x1="46" y1="92" x2="634" y2="92" stroke="#730e07" stroke-width="1"></line>

        
        <g>
          <circle cx="46" cy="92" r="6" fill="#730e07"></circle>
          <text x="46" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1922</text>
          <text x="46" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Insulin saves a life</text>
        </g>

        
        <g>
          <circle cx="164" cy="92" r="6" fill="#730e07"></circle>
          <text x="164" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1953</text>
          <text x="164" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Oxytocin synthesized</text>
        </g>

        
        <g>
          <circle cx="282" cy="92" r="6" fill="#730e07"></circle>
          <text x="282" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1963</text>
          <text x="282" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Solid-phase synthesis</text>
        </g>

        
        <g>
          <circle cx="400" cy="92" r="6" fill="#730e07"></circle>
          <text x="400" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">1984</text>
          <text x="400" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Merrifield Nobel</text>
        </g>

        
        <g>
          <circle cx="518" cy="92" r="6" fill="#730e07"></circle>
          <text x="518" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="500" fill="#1a1614">2017</text>
          <text x="518" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#4a423d" font-weight="500">Semaglutide approved</text>
        </g>

        
        <g>
          <circle cx="634" cy="92" r="8" fill="#730e07" stroke="#faf6f0" stroke-width="2"></circle>
          <circle cx="634" cy="92" r="14" fill="none" stroke="#730e07" stroke-width="1" opacity="0.4"></circle>
          <text x="634" y="68" text-anchor="middle" font-family="Cormorant Garamond, serif" font-size="22" font-weight="600" fill="#730e07">2026</text>
          <text x="634" y="123" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#730e07" font-weight="600">FDA reversal</text>
        </g>
      </svg>
      <div class="diagram-caption">A century of peptide medicine</div>
    </div>

    <p>Today there are more than eighty peptide drugs approved by the FDA, with hundreds more in clinical trials. The most famous, by an enormous margin, are the GLP-1 receptor agonists: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Both are modified versions of natural peptides your body already makes. Semaglutide is so closely related to your own GLP-1 that it differs by only two amino-acid changes and an attached fatty acid, small chemical modifications that let it last about a week in the body instead of the few minutes the natural hormone survives.</p>

    <p>But the GLP-1s are only the public face of the peptide era. Quietly, in clinics and compounding pharmacies, a wider category of peptides is being used to support tissue repair, growth hormone signaling, sexual function, immune modulation, and cellular aging. Some of these, such as sermorelin, oxytocin, and GHK-Cu, are nearly identical to molecules your body already produces. Others are designed copies of peptides found elsewhere in nature.</p>

    
    <div class="pullquote">
      <p>The common thread is that they are all <span class="mark">messengers</span>. They don't push the body to do something it wasn't built to do; they ask it to do something it already knows how to do.</p>
    </div>

  </div>
</article>

<section class="sources">
  <div class="container">
    <h3>Sources &amp; further reading</h3>
    <ol>
      <li>National Human Genome Research Institute. <em>The Human Genome Project Completion: Frequently Asked Questions.</em> genome.gov. (Approximate count of human protein-coding genes.)</li>
      <li>Nelson, D. L., &amp; Cox, M. M. <em>Lehninger Principles of Biochemistry,</em> 8th ed. W. H. Freeman, 2021. (Standard convention for peptide vs. protein length.)</li>
      <li>Bliss, M. <em>The Discovery of Insulin.</em> University of Chicago Press, 1982. University of Toronto Banting Digital Library. (Leonard Thompson, January 1922.)</li>
      <li>Merrifield, R. B. (1963). "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide." <em>Journal of the American Chemical Society</em> 85(14): 2149–2154. Nobel Prize in Chemistry, 1984.</li>
      <li>du Vigneaud, V., et al. (1953). "The Synthesis of an Octapeptide Amide With the Hormonal Activity of Oxytocin." <em>Journal of the American Chemical Society</em> 75: 4879–4880. Nobel Prize in Chemistry, 1955.</li>
      <li>Lau, J. L., &amp; Dunn, M. K. (2018). "Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions." <em>Bioorganic &amp; Medicinal Chemistry</em> 26(10): 2700–2707.</li>
      <li>Lau, J., et al. (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." <em>Journal of Medicinal Chemistry</em> 58(18): 7370–7380.</li>
      <li>UniProtKB Human Reference Proteome and PeptideAtlas (peptideatlas.org). (Catalogued bioactive peptides.)</li>
    </ol>
  </div>
</section>

Peptides without the jargon: a plain-English explanation of what they actually are, why your body already makes thousands of them, and why a small handful are reshaping modern medicine.

The science of
optimization.

The Day the Peptide Rules Changed

Hollywood's Worst-Kept Secret

Cost-Plus, Explained

The Coenzyme That Runs Out

From Vial to Receptor

503A vs 503B

Where Andrew Huberman Lands on Peptides

Why GLP-1 Works When Willpower Doesn't

"Research Grade" Is Not What You Think

Why pru Exists

The Messenger Molecules

The science ofoptimization.

The Day the Peptide Rules Changed

Hollywood's Worst-Kept Secret

Cost-Plus, Explained

The Coenzyme That Runs Out

From Vial to Receptor

503A vs 503B

Where Andrew Huberman Lands on Peptides

Why GLP-1 Works When Willpower Doesn't

"Research Grade" Is Not What You Think

Why pru Exists

The Messenger Molecules

Stay in the loop.

The science of
optimization.